Filament Health Corp. and ATMA Journey Centers announced the recent dosing of 14 healthy subjects with Filament's natural psilocybin drug candidate in a Health Canada-approved clinical trial as part of ATMA's psychedelic-assisted therapist training program. The trial's success reflects the operational calibre of both ATMA and Filament.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0369 USD | +7.42% | +7.27% | -31.79% |
04/05 | Filament Health Corp. Announces Change to Board of Directors | CI |
03/04 | Filament Health Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-31.79% | 7.79M | |
+7.84% | 218B | |
+7.35% | 184B | |
+13.04% | 135B | |
-0.65% | 62.38B | |
+11.80% | 51.37B | |
+4.81% | 50.9B | |
+0.30% | 40.87B | |
+2.78% | 36.28B | |
+26.14% | 31.88B |
- Stock Market
- Equities
- FLHLF Stock
- News Filament Health Corp.
- Filament Health Corp. and Atma Journey Centers Inc. Announce 14 Subjects Dosed in Health Canada-Approved Psilocybin Clinical Trial